Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Seven new tumor cases reported among patients on Novartis' Zolgensma gene therapy

Nine patients who have received Novartis' spinal muscular atrophy gene therapy Zolgensma have developed tumors following their treatment, the company confirmed Thursday. Seven of those cases were disclosed for the first time. Two may be ...

Published by
Endpoints News
Evidence type
Clinical

Nine patients who have received Novartis' spinal muscular atrophy gene therapy Zolgensma have developed tumors following their treatment, the company confirmed Thursday. Seven of those cases were disclosed for the first time. Two may be ...

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Endpoints News.

Gene Delivery & Transfection

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Seven new tumor cases reported among patients on Novartis' Zolgensma gene therapy | Brilliant Blue Biosciences